The largest community of pharma leaders

Northwell Health and Cold Spring Harbor Laboratory open virtual COVID-19 clinical trial for non-hospitalized patients

MANHASSET, N.Y.–(BUSINESS WIRE)–The Feinstein Institutes for Medical Research and Cold Spring Harbor Laboratory (CSHL) are recruiting patients in a fully virtual, in-home, randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of famotidine, or PEPCID, for the outpatient treatment of the novel coronavirus disease 2019 (COVID-19) in adults. Sold over-the-counter as PEPCID, famotidine is a histamine 2 blocker used to decrease stomach acid and this clinic
Source Read More

Recent Articles